Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

PTEN dosage is essential for neurofibroma development and malignant transformation.

Gregorian C, Nakashima J, Dry SM, Nghiemphu PL, Smith KB, Ao Y, Dang J, Lawson G, Mellinghoff IK, Mischel PS, Phelps M, Parada LF, Liu X, Sofroniew MV, Eilber FC, Wu H.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19479-84. doi: 10.1073/pnas.0910398106. Epub 2009 Oct 21.

2.
3.

Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.

Salamon J, Mautner VF, Adam G, Derlin T.

Rofo. 2015 Dec;187(12):1084-92. doi: 10.1055/s-0035-1553505. Epub 2015 Sep 2. Review.

4.

Malignant peripheral nerve sheath tumor of intracranial nerve: a case series review.

Ziadi A, Saliba I.

Auris Nasus Larynx. 2010 Oct;37(5):539-45. doi: 10.1016/j.anl.2010.02.009. Review.

PMID:
20399579
5.

Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis.

Woodruff JM.

Am J Med Genet. 1999 Mar 26;89(1):23-30. Review.

PMID:
10469433
6.

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.

McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Bäsecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, Martelli AM.

J Cell Physiol. 2011 Nov;226(11):2762-81. doi: 10.1002/jcp.22647. Review.

PMID:
21302297
7.

Developmental abnormalities and cancer predisposition in neurofibromatosis type 1.

Larizza L, Gervasini C, Natacci F, Riva P.

Curr Mol Med. 2009 Jun;9(5):634-53. Review.

PMID:
19601812

Supplemental Content

Support Center